Market Analysis on Unresectable Hepatocellular Carcinoma Industry – Insights for Corporate Strategy and R&D
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Unresectable Hepatocellular Carcinoma Market from 2024 to 2025?
In recent times, there has been a slight increase in the market size for unresectable hepatocellular carcinoma. The market, currently valued at $1.98 billion in 2024, is projected to expand to $2.01 billion in 2025, reflecting a Compound Annual Growth Rate (CAGR) of 1.9%. This growth pattern in the historic period is attributable to a variety of factors such as advancements in chemotherapy, results of clinical trials, constraints in liver transplantation, a rise in cancer incidences, and increased accessibility to treatment options.
What Is the Projected Market Size of the Unresectable Hepatocellular Carcinoma Market?
Expectations are high for the unresectable hepatocellular carcinoma market size, with strong expansion forecasted in the upcoming years. The prediction suggests a surge to $2.95 billion by 2029, with a compound annual growth rate (CAGR) of 10.0%. The imminent growth during the forecast period can be ascribed to changes in healthcare policies, strategies for patient stratification, the application of real-world evidence, heightened patient advocacy and awareness, along with economic factors and dynamics. The period is set to witness key trends including precision medicine and biomarkers, integration of real-world evidence and data, multidisciplinary approaches, worldwide clinical trials and partnerships, alongside a stronger focus on patient-centric care.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12079&type=smp
Who are the Major Competitors in the Unresectable Hepatocellular Carcinoma Market Outlook?
Major companies operating in the unresectable hepatocellular carcinoma market include Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, Astrazeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Halozyme Therapeutics Inc., Innovent Biologics Inc., Sirtex Medical Limited, Blueprint Medicines Corporation, Genentech Inc., CStone Pharmaceuticals, Pharmicell Co. Ltd., Pharmaxis Ltd., Delcath Systems Inc., Yiviva Inc., Celsion Corporation, Mendus AB.
What Is Fueling Growth in the Unresectable Hepatocellular Carcinoma Market?
The surge in liver cancer rates is fueling the growth of the market for unresectable hepatocellular carcinoma. The term “liver cancer” refers to the transformation of healthy, functional liver cells into cancerous cells that multiply without restraint. Transplantation and radiofrequency ablation are typically used to treat unresectable hepatocellular carcinoma. As an example, the Journal of Hepatology, a peer-reviewed scientific journal from Switzerland, reported in October 2022 that 830,200 people worldwide succumbed to liver cancer by 2020. It is projected that between 2020 and 2040, there will be approximately 1.4 million new diagnoses of liver cancer, representing a 55.0% annual increase. In another report by the American Cancer Society, a US-based non-profit organization, it was estimated in January 2024 that 41,630 new cases of primary liver cancer and intrahepatic bile duct cancer would be diagnosed in the US in 2024. This includes 28,000 men and 13,630 women, with a prediction of 29,840 deaths (19,120 men and 10,720 women). These growing incidences of liver cancer are behind the expanding unresectable hepatocellular carcinoma market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12079&type=smp
Which Unresectable Hepatocellular Carcinoma Market Segments Are Growing the Fastest?
The unresectable hepatocellular carcinoma market covered in this report is segmented –
1) By Type: Primary, Secondary, Benign Liver Growth
2) By Treatment Type: Chemotherapy, Molecularly Targeted Therapy, Immunotherapy, Other Treatments
3) By End-Users: Hospitals, Specialty Clinics, Cancer Centers
Subsegments:
1) By Primary: Hepatocellular Carcinoma (HCC), Fibrolamellar Carcinoma, Hepatoblastoma
2) By Secondary: Metastatic Liver Cancer, Intrahepatic Cholangiocarcinoma
3) By Benign Liver Growth: Hepatic Adenoma, Focal Nodular Hyperplasia, Hemangiomas
Which Industry Trends Are Shaping the Future of the Unresectable Hepatocellular Carcinoma Market?
The introduction of innovative products is emerging as a significant trend in the unresectable hepatocellular carcinoma market. Leading companies in this market are introducing progressive products to maintain their market standing. A clear example of this was seen in October 2022, when AstraZeneca, a globally recognized pharmaceutical and biotech firm from the UK, unveiled its FDA-endorsed Imjudo (tremelimumab) in conjunction with Imfinzi, specifically for US-based patients suffering from inoperable liver cancer. This novel treatment approach, dubbed the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), comprises of a singular dose of the anti-CTLA-4 antibody Imjudo 300mg, and the anti-PD-L1 antibody Imfinzi 1500 mg, administered every four weeks. It was observed that patients undergoing this combined treatment of Imjudo and Imfinzi experienced a reduction of 22% in mortality rates compared to those undergoing sorafenib treatment.
Access The Full Report Here:
Which Countries Are Leading the Unresectable Hepatocellular Carcinoma Market?
North America was the largest region in the unresectable hepatocellular carcinoma market in 2024. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12079
This Report Delivers Insight On:
1. How big is the unresectable hepatocellular carcinoma market, and how is it changing globally?
2. Who are the major companies in the unresectable hepatocellular carcinoma market, and how are they performing?
3. What are the key opportunities and risks in the unresectable hepatocellular carcinoma market right now?
4. Which products or customer segments are growing the most in the unresectable hepatocellular carcinoma market?
5. What factors are helping or slowing down the growth of the unresectable hepatocellular carcinoma market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
